Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mochida: Profits Down Sharply due to Increase in Investment Costs
June 7, 2004
- REGULATORY NEWS IN BRIEF
June 7, 2004
- Zeria: Sales Down 1.2% to \54.3 Bil.
June 7, 2004
- PRESS SEMINR
June 7, 2004
- Ono: Consolidated Sales Rise \4.3 Bil. to \139 Bil.
May 31, 2004
- PRESS SEMINAR
May 31, 2004
- Tsumura: 4th Straight Year of Growth Marked
May 31, 2004
- OTC NEWS IN BRIEF
May 31, 2004
- Toyama Chemical: Sales Drop 49% Due to Transfer Ethical Drug Business to Taisho Toyama
May 31, 2004
- DIAGNOSTIC NEWS IN BRIEF
May 31, 2004
- Kyowa Hakko Kogyo: Sales Up Virtually, Profits Jump
May 31, 2004
- WORLD NEWS IN BRIEF
May 31, 2004
- Cost Calculation Method Should Be Replaced with Free Price System: PhRMA President
May 31, 2004
- Top-12 TSE-Listed Makers Report 0.1% Decline in Sales
May 31, 2004
- BUSINESS NEWS IN BRIEF
May 31, 2004
- Meet the Leaders (31)
May 31, 2004
- BULLETIN
May 31, 2004
- Japanese Healthcare Q&A (8)
May 31, 2004
- Approval of Preventive Use of Tamiflu Recommended
May 31, 2004
- Annual Business Results
May 31, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…